SCHEMBL5600660

SCHEMBL5600660

COc1ccc2ccsc2c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 4/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA7 P43166 2/20 0.50
CA14 Q9ULX7 2/20 0.50
ECE1 P42892 2/20 0.43
FEN1 P39748 3/20 0.43
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
TPMT P51580 1/20 0.40
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
CSNK2A1 P68400 2/20 0.37
ERCC5 P28715 1/20 0.37
ALOX5 P09917 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8184428 0.85 KDM4E (0.44) CA9CA12FEN1KDM4EALDH1A1
SCHEMBL6237002 0.77 TDP1 (0.36) FEN1L3MBTL1ALDH1A1ERCC5MAPK1
SCHEMBL8996451 0.75 CA12 (0.74) CA9CA12CA1CA2CA7
SCHEMBL6233852 0.75 CA12 (0.43) CA9CA12CA1CA2CA7
SCHEMBL3807870 0.74 FEN1 (0.37) FEN1CSNK2A1ERCC5
SCHEMBL3963199 0.73 MAPT (0.47) CA9CA12CA1CA2CA7
SCHEMBL10926394 0.73 IDO1 (0.40) KDM4EALDH1A1TSHRMAPK1RAB9A
SCHEMBL19731266 0.72 CA12 (0.51) CA9CA12CA1CA2CA7
SCHEMBL19756640 0.72 ALDH1A1 (0.42) ECE1KDM4EALDH1A1TSHRCSNK2A1
SCHEMBL19756638 0.72 MAPT (0.36) ECE1ALDH1A1TSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7273856-B2 Linear basic compounds having NK-2 antagonist activity and formulations thereof MENARINI RICERCHE S.P.A. (IT) 2007-09-25 US disclosed
EP-0945450-B1 FUSED HETEROCYCLIC BENZENECARBOXYLIC ACID AMIDE DERIVATIVES AND PGD2 ANTAGONISTS CONTAINING THE SAME SHIONOGI & CO (JP) 2005-05-11 EP disclosed
US-20040259930-A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) 2004-12-23 US disclosed
US-6069166-A INHIBITORY ACTIVITY AGAINST INFILTRATION OF EOSIONOPHILS, AND ARE USEFUL AS DRUGS FOR TREATING NASAL BLOCKAGE SHIONOGI & CO., LTD. (JP) 2000-05-30 US disclosed
EP-0945450-A1 FUSED HETEROCYCLIC BENZENECARBOXYLIC ACID AMIDE DERIVATIVES AND PGD2 ANTAGONISTS CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 1999-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259930-A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof BDKRB2, BDKRB1, TACR2 CA9 1168/4885CA12 1322/4885CA1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.